A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark L. Van Natta et al. · Hepatology · 2005 · 10.7K citations

Medicine, Pathology, Gastroenterology +16

Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

Jeffrey D. Browning, Lidia S. Szczepaniak, Robert L. Dobbins et al. · Hepatology · 2004 · 3.7K citations

Medicine, Endocrinology, Internal Medicine +12

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology · 2014 · 2.3K citations · Full text

Medicine, Internal Medicine, Pathology +17

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Renata Belfort, Stephen A. Harrison, Kenneth Brown et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score and the Histopathologic Diagnosis in NAFLD: Distinct Clinicopathologic Meanings §Δ

Elizabeth M. Brunt, David E. Kleiner, Laura Wilson et al. · Hepatology · 2010 · 1.2K citations · Full text

Medicine, Pathology, Gastroenterology +16